CKD 519

Drug Profile

CKD 519

Alternative Names: CKD-519

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chong Kun Dang
  • Class Antihyperlipidaemics
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dyslipidaemias

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in South Korea (PO, Tablet)
  • 19 Jun 2017 Chong Kun Dang Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (PO, Tablet) (NCT03175835)
  • 08 May 2017 Chong Kun Dang Pharmaceutical initiates enrolment in a phase I trial in Healthy volunteers in South Korea (NCT03175835)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top